CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

Commentary
Podcast

In Partnership With:

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Taiho Pharmaceutical, John H. Strickler, MD, moderated an OncLive Inside the Clinic discussion about adverse effect (AE) management for patients with colorectal cancer (CRC). Strickler is an associate professor of medicine and a member of the Duke Cancer Institute in Durham, North Carolina.

Strickler was joined by Michael Leung, PharmD, BCOP, a clinical pharmacy specialist in Gastrointestinal (GI) Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston; Arvind N. Dasari, MD, MS, an associate professor in the Department of GI Medical Oncology in the Division of Cancer Medicine at MD Anderson; and Margot O’Neill, PA-C, MHS, a physician assistant in oncology at the Duke Cancer Institute.

In our exclusive interview, the panelists discussed AE monitoring and management with trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with previously treated, metastatic CRC; prophylactic and reactive AE management strategies when using regorafenib (Stivarga) for patients with advanced disease; and how real-world clinical experience with fruquintinib (Fruzaqla) has driven AE management for patients with metastatic disease who are receiving this agent.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Taiho Pharmaceutical. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Elias Jabbour, MD
Samer A. Srour, MB ChB, MS
Christina L. Roland, MD, MS, FACS
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS